DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT07382388

Not yet recruiting

A Real-World Study on the Impact of Weight Loss on Treatment Efficacy in Overweight/Obese Patients With Plaque Psoriasis

Assets

GLP-1 / incretin class catch-all / Semaglutide / Tirzepatide

Listed sites

0

Recruiting sites

—

Enrollment

70

estimated

Study population

Obesity / overweight, Psoriasis / psoriatic arthritis

Key I/E criterion

—

Primary endpoint

•Proportion of PASI<3

Identifiers

Registered as

NCT IDNCT07382388
Org study IDM20260001

Timeline

Milestones

Study start2026-01-28estimated
Study first posted2026-02-02actual
Last update posted2026-02-02actual
Primary completion2027-12-31estimated
Study completion2027-12-31estimated

Assets

Investigational agents

GLP-1 / incretin class catch-allSemaglutideTirzepatide

Study populations

Who this study enrolls

Obesity / overweightPsoriasis / psoriatic arthritis

Eligibility

Who can enroll

Minimum age18 Years
SexAll
Healthy volunteersNot accepted
Sampling methodNon probability sample

Study population text

Clinical diagnosis of plaque psoriasis and Body Mass Index (BMI) categorized as overweight or obese.

Inclusion criteria

1. Age ≥ 18 years, regardless of gender.

2. Having signed the informed consent form.

3. Clinical diagnosis of plaque psoriasis.

4. Body Mass Index (BMI) categorized as overweight or obese.

5. For female patients: No plans for pregnancy or oocyte donation during the study period and voluntary use of highly effective physical contraception.

Exclusion criteria

1. Pregnant or lactating women.

2. Individuals deemed by the investigator to be unsuitable for participation in this study.

Endpoints (5)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Other clinical outcomes
3
Weight & body composition
1
Patient-reported / QoL
1

Weight & body composition

1 endpoint
Secondary/protocol endpoint

Changes of BMI

Time frame:Week 12 and Week 24

BMI, change

change from baseline, improvement

Patient-reported / QoL

1 endpoint
Secondary/protocol endpoint

Proportion of DLQI<6

Time frame:Week 12 and Week 24

threshold achievement, improvement

Other clinical outcomes

3 endpoints
Primary/protocol endpoint

Proportion of PASI<3 at Week 24

Time frame:Week 24

threshold achievement, improvement

Secondary/protocol endpoint

Proportion of PASI<3 at Week 12

Time frame:Week 12

threshold achievement, improvement

Secondary/protocol endpoint

Proportion of PGA 0/1 (Physician's Global Assessment)

Time frame:Week 12 and Week 24

threshold achievement, improvement

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.